WISE enters September with a quietly contrarian setup: while the payments sector took heavy losses last week, Wise barely budged — and the borrow market tells a story of shorts stepping away, not doubling down.
The peer divergence is the most striking feature of the week. AFRM fell 9% on the week and PSFE dropped more than 6%. RKT lost 7.5%. RELY slipped 3.3%. Wise, by contrast, shed less than 0.2% across the same five sessions, closing at 920p on Tuesday. That kind of relative calm in a sector-wide sell-off either reflects genuine defensiveness or signals that the stock is simply thin in terms of active positioning — the data leans toward the latter, and not in a worrying way.
The lending market paints an unusually relaxed picture. Availability has exploded to nearly 5,824% — meaning there are almost sixty shares available to borrow for every one already on loan. That is comfortably above the 52-week floor of 728%, and availability has more than doubled in a single week. Cost to borrow is running at just 0.56%, roughly a fifth of a typical borrow cost for a liquid UK mid-cap. The ORTEX short score has been drifting lower all month, from 36.3 on August 25 to 33.4 now — the score's direction of travel is removing rather than adding short-side pressure. Taken together, the borrow market is as loose as it has been all year, and the structural demand for shorts is fading.
The Street remains constructively positioned. The consensus is a buy, with eleven analysts on that side of the ledger and a mean price target of £11.62 — roughly 21% above Tuesday's close of 920p. No recent analyst rating changes are on record, so the positive lean reflects the accumulated view rather than any fresh catalyst. On valuation, the price-to-earnings multiple has drifted higher over the past month, up roughly 5.8 turns to sit near 24.6x. Price-to-book has moved similarly. One factor score stands out: the 12-month forward EPS growth rank lands in the 99th percentile of the coverage universe, meaning almost no stock in the database is showing more aggressive forward earnings growth estimates. That is partly a base-effect story — as the recent stock-score note flagged, the forward EPS expansion measure reflects a very low prior-year base — but it does underpin why the multiple has been creeping higher.
Ownership is broadly stable at the top. Founder Kristo Kaarmann holds 18.2% and filed a 13G as recently as August 11, a passive disclosure with no activist intent. Baillie Gifford sits at 10.5% with a 13G filed in June, and Orbis filed at 5.5% in mid-August after adding nearly 9.8 million shares in the last reported quarter. Capital Research and Management added 5.5 million shares in the same period. There are no Schedule 13D filings — no activist on the register. The insider picture is messier on the surface but routine underneath: the CTO and a senior officer sold shares in mid-July, but those sales followed same-day share awards and at low significance scores. The 90-day net insider position is actually marginally positive in share terms, at roughly 142,000 shares net — not a conviction signal in either direction, but not a red flag either. As always with 13G disclosures, stakes are as-last-disclosed around the 5% threshold, and a holder dropping below that level may not file again.
One forward marker is worth noting: the next earnings event is not scheduled until November 6. The most recent print in late June produced a sharp one-day gain of 8.5%, followed by a 14.5% five-day move — a markedly different reaction pattern from the July 16 release, which reversed 4.5% on the day. The question heading into November is whether the forward EPS story holds at current multiples, or whether the valuation gap to the analyst consensus begins to close — from which direction is the part that remains open.
See the live data behind this article on ORTEX.
Open WISE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
